GPT and chronic hepatitis B virus infection: The criteria for the indication of reimbursed antiviral therapy for chronic hepatitis B in Taiwan were as the followings: (1) for cirrhotic patients, serum HBV DNA levels >2000 IU/mL irrespective of serum alanine aminotransferase (ALT) levels; (2) for non-cirrhotic patients, serum ALT levels >80 U/L in addition to serum HBV DNA levels >20000 IU/mL in HBeAg-positive patients and HBVDNA levels >2000 IU/mL in HBeAg-negative patients, respectively.